Literature DB >> 23896639

Characterizations of HCV NS5A replication complex inhibitors.

Donald R O'Boyle Ii1, Jin-Hua Sun, Peter T Nower, Julie A Lemm, Robert A Fridell, Chunfu Wang, Jeffrey L Romine, Makonen Belema, Van N Nguyen, Denis R St Laurent, Michael Serrano-Wu, Lawrence B Snyder, Nicholas A Meanwell, David R Langley, Min Gao.   

Abstract

The hepatitis C virus NS5A protein is an established and clinically validated target for antiviral intervention by small molecules. Characterizations are presented of compounds identified as potent inhibitors of HCV replication to provide insight into structural elements that interact with the NS5A protein. UV-activated cross linking and affinity isolation was performed with one series to probe the physical interaction between the inhibitors and the NS5A protein expressed in HCV replicon cells. Resistance mapping with the second series was used to determine the functional impact of specific inhibitor subdomains on the interaction with NS5A. The data provide evidence for a direct high-affinity interaction between these inhibitors and the NS5A protein, with the interaction dependent on inhibitor stereochemistry. The functional data supports a model of inhibition that implicates inhibitor binding by covalently combining distinct pharmacophores across an NS5A dimer interface to achieve maximal inhibition of HCV replication.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiviral; Covalent attachment; Daclatasvir; HCV; NS5A dimer; NS5A replication complex inhibitor

Mesh:

Substances:

Year:  2013        PMID: 23896639     DOI: 10.1016/j.virol.2013.06.032

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  Cyclophilin A allows the allosteric regulation of a structural motif in the disordered domain 2 of NS5A and thereby fine-tunes HCV RNA replication.

Authors:  Marie Dujardin; Vanesa Madan; Neha S Gandhi; François-Xavier Cantrelle; Hélène Launay; Isabelle Huvent; Ralf Bartenschlager; Guy Lippens; Xavier Hanoulle
Journal:  J Biol Chem       Date:  2019-07-17       Impact factor: 5.157

2.  Synergistic Activity of Combined NS5A Inhibitors.

Authors:  Donald R O'Boyle; Peter T Nower; Min Gao; Robert Fridell; Chunfu Wang; Piyasena Hewawasam; Omar Lopez; Yong Tu; Nicholas A Meanwell; Makonen Belema; Susan B Roberts; Mark Cockett; Jin-Hua Sun
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

3.  The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.

Authors:  Udayan Chatterji; Jose A Garcia-Rivera; James Baugh; Katarzyna Gawlik; Kelly A Wong; Weidong Zhong; Clifford A Brass; Nikolai V Naoumov; Philippe A Gallay
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

4.  Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.

Authors:  David R McGivern; Takahiro Masaki; Sara Williford; Paul Ingravallo; Zongdi Feng; Frederick Lahser; Ernest Asante-Appiah; Petra Neddermann; Raffaele De Francesco; Anita Y Howe; Stanley M Lemon
Journal:  Gastroenterology       Date:  2014-04-22       Impact factor: 22.682

5.  Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.

Authors:  Vineela Chukkapalli; Kristi L Berger; Sean M Kelly; Meryl Thomas; Alexander Deiters; Glenn Randall
Journal:  Virology       Date:  2014-12-26       Impact factor: 3.616

6.  The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors.

Authors:  Sebastian M Lambert; David R Langley; James A Garnett; Richard Angell; Katy Hedgethorne; Nicholas A Meanwell; Steve J Matthews
Journal:  Protein Sci       Date:  2014-04-05       Impact factor: 6.725

7.  NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes.

Authors:  V Reghellin; L Donnici; S Fenu; V Berno; V Calabrese; M Pagani; S Abrignani; F Peri; R De Francesco; P Neddermann
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

8.  Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.

Authors:  Chunfu Wang; Lingling Jia; Donald R O'Boyle; Jin-Hua Sun; Karen Rigat; Lourdes Valera; Peter Nower; Xin Huang; Bernadette Kienzle; Susan Roberts; Min Gao; Robert A Fridell
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

9.  Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance.

Authors:  Lize Cuypers; Guangdi Li; Pieter Libin; Supinya Piampongsant; Anne-Mieke Vandamme; Kristof Theys
Journal:  Viruses       Date:  2015-09-16       Impact factor: 5.048

Review 10.  Approaches to hepatitis C treatment and cure using NS5A inhibitors.

Authors:  James J Kohler; James H Nettles; Franck Amblard; Selwyn J Hurwitz; Leda Bassit; Richard A Stanton; Maryam Ehteshami; Raymond F Schinazi
Journal:  Infect Drug Resist       Date:  2014-03-05       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.